Visualizing beta cells in morbid obese patients with T2D before and after bariatric surgery
- Conditions
- Type 2 Diabetes1001842410017998
- Registration Number
- NL-OMON42099
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
- Morbid obese T2D patient who will undergone RYGB at the Rijnstate in Arnhem (BMI > 35 kg/m2)
- Female
- Signed informed consent;Mild T2D group
o C-peptide > 1.3 nmol/l
o T2D diagnosis < 2 years before RYGB
o Only metformin usage as anti-diabetic medication;Severe T2D group
o C-peptide < 1 nmol/l
o T2D diagnosis > 4 years before RYGB
o Insulin and/or sulfonylurea (SU) usage
- Fasting glucose < 7 mmol/l at time C-peptide was determined (Aarts et al. 2013)
- Known liver failure or serum liver values over 2 times normal value at the time of standard laboratory assessment.
- BMI > 50 kg/m2
- Previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors
- Pregnancy or the wish to become pregnant within 18 months
- Breast feeding
- Kidney failure, i.e. calculated creatinine clearance below 40ml/min
- Age <18 years
- No signed informed consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method